BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

被引：0
|
作者：
Marcel Ebeling
Mario Scheurer
Andreas Sakkas
Sebastian Pietzka
Alexander Schramm
Frank Wilde
机构：
[1] Academic Hospital of the University of Ulm,Department of Oral and Plastic Maxillofacial Surgery, Military Hospital Ulm
[2] University Hospital Ulm,Department of Oral and Plastic Maxillofacial Surgery
来源：
Medical Oncology | / 40卷
关键词：
Ameloblastoma; BRAF; Facial reconstruction; Chemotherapy; Dabrafenib; Vemurafenib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib
    Robinson, Sara D.
    O'Shaughnessy, Joyce A.
    Cowey, C. Lance
    Konduri, Kartik
    LUNG CANCER, 2014, 85 (02) : 326 - 330
  • [42] Vemurafenib Treatment of BRAF V600E-Mutated Malignant Peripheral Nerve Sheath Tumor
    Kaplan, Henry G.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (12): : 1466 - 1470
  • [43] DRAMATIC RESPONSE OF A BRAF V600E-MUTATED PRIMARY CNS HISTIOCYTIC SARCOMA TO VEMURAFENIB
    Idbaih, Ahmed
    Mokhtari, Karima
    Emile, Jean-Francois
    Galanaud, Damien
    Belaid, Hayat
    de Bernard, Simon
    Benameur, Neila
    Barlog, Vlad-Ciprian
    Psimaras, Dimitri
    Donadieu, Jean
    Carpentier, Catherine
    Martin-Duverneuil, Nadine
    Haroche, Julien
    Feuvret, Loic
    Zahr, Noel
    Delattre, Jean-Yves
    Khe Hoang-Xuan
    NEUROLOGY, 2014, 83 (16) : 1478 - 1480
  • [44] Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report
    Francesco Gelsomino
    Alessandro Di Federico
    Maria Lucia Tardio
    Giada Grilli
    Antonietta D’Errico
    Andrea Ardizzoni
    Stefania Salvagni
    Investigational New Drugs, 2022, 40 : 190 - 193
  • [45] Drug-induced colitis on BRAF and MEK inhibitors for BRAF V600E-mutated non-small cell lung cancer: a case report
    Gelsomino, Francesco
    Di Federico, Alessandro
    Tardio, Maria Lucia
    Grilli, Giada
    D'Errico, Antonietta
    Ardizzoni, Andrea
    Salvagni, Stefania
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (01) : 190 - 193
  • [46] BRAF inhibitors in BRAF-V600 mutated primary neuroepithelial brain tumors
    Preusser, Matthias
    Bienkowski, Michal
    Birner, Peter
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (01) : 7 - 14
  • [47] Case report: Metastatic BRAF V600E-mutated adult Wilms' tumor with robust response to BRAF/MEK inhibitor therapy
    Kroll, Matthew R.
    Au, Cherry
    Slostad, Jessica
    Christ, Trevor N.
    Papas, Sam G.
    Tan, Alan
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [48] Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
    Smalley, Keiran S. M.
    Lioni, Mercedes
    Palma, Maurizia Dalla
    Xiao, Min
    Desai, Brijal
    Egyhazi, Suzanne
    Hansson, Johan
    Wu, Hong
    King, Alastair J.
    Van Belle, Patricia
    Elder, David E.
    Flaherty, Keith T.
    Herlyn, Meenhard
    Nathanson, Katherine L.
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (09) : 2876 - 2883
  • [49] Specific activation of glycolytic enzyme enolase 2 in BRAF V600E-mutated colorectal cancer
    Yukimoto, Ryohei
    Nishida, Naohiro
    Hata, Tsuyoshi
    Fujino, Shiki
    Ogino, Takayuki
    Miyoshi, Norikatsu
    Takahashi, Hidekazu
    Uemura, Mamoru
    Satoh, Taroh
    Hirofumi, Yamamoto
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Eguchi, Hidetoshi
    CANCER SCIENCE, 2021, 112 (07) : 2884 - 2894
  • [50] Cost-effectiveness of encorafenib plus cetuximab in BRAF V600E-mutated colorectal cancer
    Giuliani, Jacopo
    Mantoan, Beatrice
    Bonetti, Andrea
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (01) : 199 - 202
12345